BertHO'NeilMD

Oncology • Indianapolis, IN

Professor of Oncology, Indiana University

Join to view full profile

Dr. O'Neil is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. O'Neil's full profile

Already have an account?

Office
550 University Blvd
Indianapolis, IN 46202
Phone+1 317-944-5000

Fax+1 317-944-4319
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1998 - 2001
University of California (San Francisco)Residency, Internal Medicine, 1994 - 1997
David Geffen School of Medicine at UCLAClass of 1994

Certifications & Licensure

CA State Medical License 1996 - Present
IN State Medical License 2013 - 2025
NC State Medical License 2001 - 2014
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer Start of enrollment: 2004 Aug 01
Completed
Phase 1
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer Start of enrollment: 2003 Apr 01
Completed
Phase 1
Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Start of enrollment: 2003 Dec 01
Completed
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer Start of enrollment: 2006 Oct 01
Completed
Phase 2
Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer Start of enrollment: 2005 Mar 01
Completed
Phase 2
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab Start of enrollment: 2008 Mar 01
Terminated
Phase 2
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 2
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment Start of enrollment: 2008 Mar 01
Completed
Phase 1
Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis Start of enrollment: 2008 Oct 01
Terminated
Phase 1
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status Start of enrollment: 2009 May 01
Completed
Phase 2
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Start of enrollment: 2009 Jul 22
Completed
Phase 1
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Jul 19
Completed
Phase 1, Phase 2
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Start of enrollment: 2011 Apr 07
Completed
Phase 2
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study Start of enrollment: 2012 Oct 01
Completed
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy Start of enrollment: 2012 Oct 01
Completed
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors Start of enrollment: 2013 Jun 01
Completed
Phase 1
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer Start of enrollment: 2013 Dec 01
Terminated
Phase 1, Phase 2
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer Start of enrollment: 2014 May 01
Active, not recruiting
Phase 2
BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
Terminated
Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancreas Start of enrollment: 2014 Jul 01
Withdrawn
A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors Start of enrollment: 2015 Apr 07
Completed
Phase 1
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors Start of enrollment: 2015 Jul 13
Terminated
Phase 1, Phase 2
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma Start of enrollment: 2016 Jul 18
Terminated
Phase 1, Phase 2
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Start of enrollment: 2016 Jan 01
Completed
Phase 1
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body Start of enrollment: 2016 Mar 08
Completed
Phase 1
Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma Start of enrollment: 2019 Dec 01
Not yet recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

13 citations
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186
Cameron Herting, Matthew R. Farren, Yan Tong, Ziyue Liu, Bert H. O'Neil, Tanios Bekaii-Saab, Anne M. Noonan, Christopher McQuinn, Thomas A. Mace, Walid L. Shaib, Chris...> ;Cancer Immunology, Immunotherapy. 2021 Jun 23
11 citations
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Nuria Kotecki, P. Vuagnat, Bert H. O'Neil, Shadia I. Jalal, Sylvie Rottey, Hans Prenen, Karim A. Benhadji, Meng Xia, Anna M. Szpurka, Abhijoy Saha, Johan Wallin, Subha...> ;Journal of Immunotherapy. 2021 Apr 28
5 citations
IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results from CALGB (Alliance)/SWOG 80405
Brendan J. Guercio, Sui Zhang, Fang-Shu Ou, Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michael Pollak, Andrew B. Nixon, Brian C. Mullen, ...> ;JNCI Cancer Spectrum. 2021 Jan 5
4 citations
Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial.
Erin L. Van Blarigan, Sui Zhang, Fang-Shu Ou, Alan Venlo, Kimmie Ng, Chloe E. Atreya, Katherine Van Loon, Donna Niedzwiecki, Edward Giovannucci, Eric G. Wolfe, Heinz-J...> ;JAMA Network Open. 2020 Oct 1
24 citations
Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer
Christopher Mackintosh, Chen Yuan, Fang-Shu Ou, Sui Zhang, Donna Niedzwiecki, I-Wen Chang, Bert H. O'Neil, Brian C. Mullen, Heinz-Josef Lenz, Charles D. Blanke, Alan P...> ;JAMA Oncology. 2020 Nov 1
32 citations
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer
Efrat Dotan, Dana Backlund Cardin, Heinz-Josef Lenz, Wells A. Messersmith, Bert H. O'Neil, Steven J. Cohen, Crystal S. Denlinger, Safi Shahda, Igor Astsaturov, Ann M. ...> ;Clinical Cancer Research. 2020 Jul 21
87 citations
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Janice M. Mehnert, Emily K. Bergsland, Bert H. O'Neil, Armando Santoro, Jan H.M. Schellens, Roger B. Cohen, Toshihiko Doi, Patrick A. Ott, Michael J. Pishvaian, Igor P...> ;Cancer. 2020 Jul 1
7 citations
Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405
Brendan J. Guercio, Sui Zhang, Alan P. Venook, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Brian C. Mullen, Bert H. O'Neil, James Edward Shaw...> ;JNCI Cancer Spectrum. 2020 Mar 31
61 citations
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastat...
S. Lindsey Davis, Dana Backlund Cardin, Safi Shahda, Heinz-Josef Lenz, Efrat Dotan, Bert H. O'Neil, Ann M. Kapoun, Jordan Berlin, Wells A. Messersmith, Steven J. Cohen> ;Investigational New Drugs. 2020 Jun 1
101 citations
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
, , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2020 May 1
21 citations
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)
Justin C. Brown, Sui Zhang, Fang-Shu Ou, Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Cryst...> ;JNCI Cancer Spectrum. 2020 Feb 1
505 citations
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O'Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Tan...> ;Journal of Clinical Oncology. 2020 Jan 1
40 citations
Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).
Chen Yuan, Kaori Sato, Bruce W. Hollis, Sui Zhang, Donna Niedzwiecki, Fang-Shu Ou, I-Wen Chang, Bert H. O'Neil, Federico Innocenti, Heinz-Josef Lenz, Charles D. Blanke...> ;Clinical Cancer Research. 2019 Dec 15
79 citations
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Sarina Anne Piha-Paul, Jasgit C. Sachdev, Minal A. Barve, Patricia LoRusso, Russell Z. Szmulewitz, Sapna Pradyuman Patel, Primo N. Lara, Xiaotian Chen, Beibei Hu, Kevi...> ;Clinical Cancer Research. 2019 Nov 1
1126 citations
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Nature. 2019 Oct 30
8 citations
Tissue/site-agnostic study of ribociclib for tumors with cyclin D-CDK4/6 pathway genomic alterations: A Phase II, open-label, single-arm basket study
Julio Antonio Peguero, Davendra Sohal, Bert H. O'Neil, Howard Safran, Karen Kelly, Juneko E. Grilley-Olson, Vivek Subbiah, Lincoln Nadauld, Das Purkayastha, Erica Stea...> ;JCO Precision Oncology. 2019 Aug 16
44 citations
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405
Brendan J. Guercio, Sui Zhang, Fang-Shu Ou, Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H. O'Neil, James Edward Shaw, Blase N. Polite...> ;Journal of Clinical Oncology. 2019 Aug 13
12 citations
Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Olumide B. Gbolahan, Neda Hashemi-Sadraei, Bert H. O'Neil> ;Journal of the National Comprehensive Cancer Network. 2019 Jun 1
27 citations
Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
Hanna K. Sanoff, Dominic H. Moon, Dominic T. Moore, Jeremiah C. Boles, Courtney Bui, William Blackstock, Bert H. O'Neil, Somasundaram Subramaniam, Autumn J. McRee, Che...> ;Nanomedicine. 2019 Jun 1
11 citations
Social correlates of mental health in gastrointestinal cancer patients and their family caregivers: Exploring the role of loneliness
Ekin Secinti, Kevin L. Rand, Shelley A. Johns, Bert H. O'Neil, Paul R. Helft, Safi Shahda, Shadia I. Jalal, Catherine E. Mosher> ;Supportive Care in Cancer. 2019 Jun 1
25 citations
Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study
Olumide B. Gbolahan, Yan Tong, Amikar Sehdev, Bert H. O'Neil, Safi Shahda> ;BMC Cancer. 2019 May 17
28 citations
Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma.
Jennifer Wu, Merly Contratto, Krishna Shanbhogue, Gulam Abbas Manji, Bert H. O'Neil, Anne M. Noonan, Robert Tudor, Ray Lee> ;World Journal of Clinical Oncology. 2019 Mar 24
34 citations
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.
Mohamad Bassam Sonbol, Daniel H. Ahn, David Goldstein, Takuji Okusaka, Josep Tabernero, Teresa Macarulla, Michele Reni, Chung Pin Li, Bert O'Neil, Eric Van Cutsem, Tan...> ;Future Oncology. 2019 Feb 15
21 citations
Update on systemic therapy for colorectal cancer: biologics take sides
Olumide B. Gbolahan, Bert H. O'Neil> ;Translational Gastroenterology and Hepatology. 2019 Feb 13
529 citations
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Acro...
Patrick A. Ott, Yung-Jue Bang, Sarina Anne Piha-Paul, Albiruni Ryan Abdul Razak, Jaafar Bennouna, Jean-Charles Soria, Hope S. Rugo, Roger B. Cohen, Bert H. O'Neil, Jan...> ;Journal of Clinical Oncology. 2019 Feb 1
Join now to see all

Journal Articles

Phase I Study of EUS-Guided Photodynamic Therapy for Locally Advanced Pancreatic Cancer
John M Dewitt, Bert O'Neil, Amikar Sehdev, Safi Shahda, Gastrointestinal Endoscopy

Lectures

Gene expression and cytokine modulation in a first in human (FIH) study of a pan BET inhibitor ABBV-075 in solid tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Grant Support

Radiation-Induced Signaling And Treatment ResistanceNational Cancer Institute2006–2010
Clinical Trial: A Phase II Study Of AZD6244 In Advanced Or Metastatic HepatocellNational Center For Research Resources2008
Role Of Intestinal Ugt'S On Irinotecan DispositionNational Center For Research Resources2004–2006

Hospital Affiliations

Richard L. Roudebush Veterans Affairs Medical CenterIndianapolis, Indiana
Indiana University Health University HospitalIndianapolis, Indiana

BertHO'NeilMD

Dr. O'Neil is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Grant Support

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.